Zai Lab Future Growth

Future criteria checks 5/6

Zai Lab is forecast to grow earnings and revenue by 62% and 32.2% per annum respectively. EPS is expected to grow by 62.2% per annum. Return on equity is forecast to be -9.1% in 3 years.

Key information

62.0%

Earnings growth rate

62.2%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	32.2%
Future return on equity	-9.1%
Analyst coverage	Good
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24

China accepts Zai Lab's biologics license application for neuromuscular disorder drug

Jul 13

Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

Jun 03

As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?

May 18

Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses

Mar 08

Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates

Mar 06

Earnings and Revenue Growth Forecasts

NasdaqGM:ZLAB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	956	83	35	136	10
12/31/2025	635	-126	-153	-92	13
12/31/2024	379	-317	-343	-295	13
12/31/2023	267	-335	-193	-198	N/A
9/30/2023	263	-301	-291	-293	N/A
6/30/2023	252	-393	-371	-364	N/A
3/31/2023	231	-410	-368	-350	N/A
12/31/2022	215	-443	-393	-368	N/A
9/30/2022	197	-593	-438	-411	N/A
6/30/2022	182	-529	-472	-446	N/A
3/31/2022	171	-554	-494	-467	N/A
12/31/2021	144	-704	-568	-549	N/A
9/30/2021	115	-569	-458	-441	N/A
6/30/2021	87	-537	-374	-359	N/A
3/31/2021	61	-454	-357	-346	N/A
12/31/2020	49	-269	-227	-216	N/A
9/30/2020	39	-239	-219	-212	N/A
6/30/2020	29	-240	-212	-200	N/A
3/31/2020	19	-201	-203	-189	N/A
12/31/2019	13	-195	-206	-191	N/A
9/30/2019	8	-212	-209	-196	N/A
6/30/2019	4	-181	N/A	N/A	N/A
3/31/2019	2	-160	N/A	N/A	N/A
12/31/2018	0	-139	-108	-98	N/A
9/30/2018	N/A	-89	N/A	N/A	N/A
6/30/2018	N/A	-67	N/A	N/A	N/A
3/31/2018	N/A	-59	N/A	N/A	N/A
12/31/2017	N/A	-50	-41	-32	N/A
9/30/2017	N/A	-50	N/A	N/A	N/A
6/30/2017	N/A	-50	N/A	-41	N/A
3/31/2017	N/A	-44	N/A	-37	N/A
12/31/2016	N/A	-38	N/A	-32	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: ZLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ZLAB is expected to become profitable in the next 3 years.

Revenue vs Market: ZLAB's revenue (32.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: ZLAB's revenue (32.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZLAB is forecast to be unprofitable in 3 years.

Zai Lab Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2026

Price target decreased by 11% to US$56.44

Consensus EPS estimates upgraded to US$3.45 loss, revenue downgraded

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Consensus EPS estimates upgraded to US$3.21 loss

Recent updates

Forecast to breakeven in 2026

A Risky Bet: Zai Lab's Uncertain Future

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Price target decreased by 11% to US$56.44

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Key Executive notifies of intention to sell stock

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Consensus EPS estimates upgraded to US$3.45 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

New minor risk - Profitability

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Insider exercised options to buy US$295k worth of stock.

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

New minor risk - Share price stability

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

Consensus EPS estimates upgraded to US$3.21 loss

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder exercised options to buy US$292k worth of stock.

Forecast to breakeven in 2025

Insider exercised options and sold US$425k worth of stock

Full year 2022 earnings released: US$4.62 loss per share (vs US$7.58 loss in FY 2021)

Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Independent Director recently sold US$278k worth of stock

Insider notifies of intention to sell stock

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 12%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer

Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Insider exercised options to buy US$157k worth of stock.

Consensus EPS estimates fall by 11%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M

Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer

Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022

China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited